Suprachoroidal injection - Clearside's approach to treating Diabetic Macular Edema

(c) NEI

Clearside Biomedical, Inc. has completed patient enrollment in the Phase 2 clinical trial (referred to as "TYBEE") of CLS-TA, the company's proprietary suspension formulation of the corticosteroid triamcinolone acetonide (TA) for suprachoroidal administration, used in combination with intravitreally administered Eylea^TM (aflibercept) for treatment of diabetic macular edema (DME).  Patient follow-up in the TYBEE trial is 6 months.